Barwon Health   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Geelong Australia (1998)

Organization Overview

First Clinical Trial
2003
NCT00430547
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Barwon Health | Barwon Health; ANZIC Research Centre

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Critical Illness (Phase 2)

Shock (Phase 2)

Shock, Septic (Phase 2)

Vasoplegia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 10